Alta Capital Management LLC Cuts Stock Holdings in Novo Nordisk A/S $NVO

Alta Capital Management LLC cut its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 92.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 23,198 shares of the company’s stock after selling 284,519 shares during the period. Alta Capital Management LLC’s holdings in Novo Nordisk A/S were worth $1,287,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. True Wealth Design LLC increased its stake in Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after acquiring an additional 300 shares during the last quarter. NewSquare Capital LLC grew its holdings in shares of Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after purchasing an additional 282 shares during the period. Guerra Advisors Inc acquired a new stake in Novo Nordisk A/S during the 3rd quarter worth approximately $25,000. Strengthening Families & Communities LLC purchased a new position in Novo Nordisk A/S in the third quarter valued at approximately $30,000. Finally, Mid American Wealth Advisory Group Inc. acquired a new position in Novo Nordisk A/S during the second quarter valued at approximately $37,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $50.35 on Wednesday. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a fifty-two week low of $43.08 and a fifty-two week high of $93.80. The business has a 50 day moving average price of $53.78 and a two-hundred day moving average price of $54.18. The firm has a market cap of $224.79 billion, a PE ratio of 14.64 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, February 4th. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The company had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Quarterly results beat expectations — Novo reported $1.01 EPS and $12.43B revenue for the quarter, topping analyst estimates and showing strong profitability metrics. MarketBeat: NVO
• Positive Sentiment: Late‑stage trial success — CagriSema outperformed semaglutide in a 68‑week type‑2 diabetes study (better HbA1c and weight loss), supporting pipeline value beyond current GLP‑1 products. Reuters: CagriSema trial
• Positive Sentiment: Full‑year 2025 sales topped forecasts — reported full‑year sales beat expectations, showing underlying demand despite competitive pressures. Barron’s: 2025 sales beat
• Neutral Sentiment: U.S. leadership changes announced — Jamey Millar named head of U.S. business (and Hong Chow head of product/portfolio strategy); routine exec moves that may affect execution but are not immediate catalysts. Reuters: U.S. appointments
• Neutral Sentiment: Analyst views mixed — some firms (e.g., Kepler) maintain positive ratings while banks (Citi) caution that more head‑to‑head data vs. competitors will matter for longer‑term positioning. Globe and Mail: Kepler rating Proactive: Citi comment
• Negative Sentiment: Bearish 2026 guidance — management forecast adjusted sales and operating profit could decline 5%–13% (constant FX) in 2026, citing U.S. price reductions and loss of exclusivity for Wegovy/Ozempic; this is the main driver of the share drop. MarketWatch: 2026 sales outlook Proactive: warns of 2026 decline
• Negative Sentiment: Pricing and competition risk — U.S. GLP‑1 prices are falling and competition (including cash‑pay channels) is intensifying, which tightens long‑term obesity market revenue potential. Reuters: Obesity market outlook

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Hsbc Global Res lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, January 9th. BMO Capital Markets set a $57.00 price objective on Novo Nordisk A/S in a research report on Monday, January 26th. Jefferies Financial Group assumed coverage on Novo Nordisk A/S in a research report on Monday, October 27th. They issued an “underperform” rating for the company. Finally, CICC Research initiated coverage on Novo Nordisk A/S in a report on Friday, January 9th. They set an “outperform” rating and a $73.50 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $57.79.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.